Home/Investors/Sequoia Capital China Sequoia Capital China
Biotech Investor · 27 portfolio companies
Portfolio Companies
| Company | Stage | Valuation | Focus |
|---|
| Genocury Biotech | preclinical | — | Oncology |
| VivaVision Biotech | commercial | — | Ophthalmology |
| Tenacia Biotechnology | phase-1 | — | Oncology, Immunology |
| Ocumension Therapeutics | phase-2 | — | Ophthalmology |
| Lyvgen Pharma | phase-2 | — | Oncology, Immunology |
| Hua Medicine | commercial | — | Metabolic |
| Escugen | preclinical | — | Genetic Disorders, Oncology |
| Full-Life Technologies | phase-2 | — | Oncology |
| ChemPartner | platform | — | — |
| Drug Farm | preclinical | — | Infectious Disease, Oncology |
| De Novo Pharmatech | platform | — | Oncology |
| Convalife Pharmaceuticals | phase-2 | — | Cardiovascular, Metabolic |
| MabPlex | platform | — | Oncology, Immunology |
| Thousand Oaks Biopharmaceuticals | phase-2 | — | Oncology, Immunology |
| Biomics Biopharma | preclinical | — | Oncology, Gene Therapy |
| Vazyme | commercial | — | Diagnostics |
| Vazyme | commercial | — | Diagnostics |
| Triastek | phase-2 | — | Gastrointestinal Diseases, Central Nervous System Diseases |
| Eaglenos Sciences | preclinical | — | Oncology |
| Quaero Life Science | phase-2 | — | Oncology, Immunology |
| AccuPulse | commercial | — | Cardiovascular, Respiratory |
| Innorna | preclinical | — | Genetics & Genomics, Oncology |
| Yirui Pharma | phase-2 | — | Oncology, Immunology |
| Venus MedTech | commercial | — | Cardiovascular |
| Qihan Biotech | preclinical | — | Oncology, Autoimmune |
| Lynk Pharmaceuticals | phase-2 | — | Oncology, Immunology |
| CSR Biotech | phase-2 | — | Oncology, Immunology |